-
公开(公告)号:US20150045445A1
公开(公告)日:2015-02-12
申请号:US14522456
申请日:2014-10-23
申请人: Anton Frenkel , Ramy Lidor-Hadas , Eliezer Bahar
发明人: Anton Frenkel , Ramy Lidor-Hadas , Eliezer Bahar
IPC分类号: A61K31/135 , C07C221/00 , C07C225/20
CPC分类号: A61K31/135 , C07C221/00 , C07C225/20 , C07C2602/08
摘要: The subject invention provides a pharmaceutical composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of 3-keto-N-propargyl-1-aminoindan or a salt thereof.
摘要翻译: 本发明提供含有N-炔丙基-1(R) - 氨基茚满或其药学上可接受的盐和3-酮-N-炔丙基-1-氨基茚满的化合物或其盐的药物组合物。
-
公开(公告)号:US07476757B2
公开(公告)日:2009-01-13
申请号:US12103310
申请日:2008-04-15
IPC分类号: C07C261/00
CPC分类号: C07C269/06 , C07B2200/07 , C07C29/143 , C07C209/16 , C07C2602/08 , C07C211/42 , C07C271/44 , C07C35/32
摘要: A process for manufacturing (R)-propynylaminoindans, and alternatively, a process for manufacturing (S)-propynylaminoindans. The chiral propynylaminoindans include alkoxy or alkylcarbamates derivatives. The process comprises transfer or pressure hydrogenation in the presenc of an optically active catalyst to reduce 1-indanones. The chiral product, either (S)- or (R)-indanols undergo nucleophilic substitution to produce the named product. In an additional aspect, the invention relates to novel intermediates and compounds, namely, substituted indanones, substituted (S)-indanols and substituted (R)-indanols.
摘要翻译: 制备(R) - 丙炔基氨基茚满的方法,或者,制备(S) - 丙炔基氨基茚满的方法。 手性丙炔基氨基茚满包括烷氧基或烷基氨基甲酸酯衍生物。 该方法包括在光学活性催化剂的存在下转移或加压氢化以还原1-茚满酮。 (S) - 或(R) - 茚满醇的手性产物经历亲核取代以产生命名的产物。 在另一方面,本发明涉及新的中间体和化合物,即取代的茚满酮,取代的(S) - 茚满醇和取代的(R) - 茚满醇。
-
公开(公告)号:US07375249B2
公开(公告)日:2008-05-20
申请号:US11358995
申请日:2006-02-21
IPC分类号: C07C211/00
CPC分类号: C07C269/06 , C07B2200/07 , C07C29/143 , C07C209/16 , C07C2602/08 , C07C211/42 , C07C271/44 , C07C35/32
摘要: A process for manufacturing (R)-propynylaminoindans, and alternatively, a process for manufacturing (S)-propynylaminoindans. The chiral propynylaminoindans include alkoxy or alkylcarbamates derivatives. The process comprises transfer or pressure hydrogenation in the presence of an optically active catalyst to reduce 1-indanones. The chiral product, either (S)- or (R)-indanols undergo nucleophilic substitution to produce the named product. In an additional aspect, the invention relates to novel intermediates and compounds, namely, substituted indanones, substituted (S)-indanols and substituted (R)-indanols.
摘要翻译: 制备(R) - 丙炔基氨基茚满的方法,或者,制备(S) - 丙炔基氨基茚满的方法。 手性丙炔基氨基茚满包括烷氧基或烷基氨基甲酸酯衍生物。 该方法包括在光学活性催化剂存在下转移或加压氢化以还原1-茚满酮。 (S) - 或(R) - 茚满醇的手性产物经历亲核取代以产生命名的产物。 在另一方面,本发明涉及新的中间体和化合物,即取代的茚满酮,取代的(S) - 茚满醇和取代的(R) - 茚满醇。
-
公开(公告)号:US06218566B1
公开(公告)日:2001-04-17
申请号:US09437700
申请日:1999-11-10
申请人: Ramy Lidor , Eliezer Bahar , Anton Frenkel
发明人: Ramy Lidor , Eliezer Bahar , Anton Frenkel
IPC分类号: C07C22900
CPC分类号: C07C227/42 , C07C229/36
摘要: A process for manufacturing a highly purified, stable, non-hygroscopic, crystalline composition of L-DOPA ethyl ester. The L-DOPA ethyl ester is an active ingredient in many pharmaceutical preparations for the treatment of patients suffering from Parkinson's Disease and related indications.
摘要翻译: 一种用于制造高纯度,稳定,非吸湿性的L-DOPA乙酯的结晶组合物的方法。 L-DOPA乙酯是用于治疗患有帕金森病和相关适应症的患者的许多药物制剂中的活性成分。
-
公开(公告)号:US5639913A
公开(公告)日:1997-06-17
申请号:US712580
申请日:1996-09-13
申请人: Ramy Lidor , Eliezer Bahar
发明人: Ramy Lidor , Eliezer Bahar
IPC分类号: A01N37/18 , A01N37/34 , A61K31/135 , A61K31/137 , A61K31/16 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/195 , A61K31/196 , A61K31/215 , A61K31/216 , A61K31/24 , A61K31/27 , A61K31/275 , A61K31/277 , C07C209/04 , C07C209/88 , C07C211/00 , C07C211/38 , C07C211/42 , C07C213/10 , C07C215/44 , C07C217/74 , C07C231/20 , C07C233/05 , C07C233/06 , C07C233/23 , C07C233/74 , C07C237/04 , C07B57/00
CPC分类号: C07C237/04 , A61K31/135 , A61K31/136 , A61K31/137 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/195 , A61K31/196 , A61K31/215 , A61K31/216 , A61K31/24 , A61K31/27 , A61K31/275 , A61K31/277 , C07C209/04 , C07C209/88 , C07C211/38 , C07C211/42 , C07C213/10 , C07C215/44 , C07C217/52 , C07C217/74 , C07C231/20 , C07C233/03 , C07C233/06 , C07C233/11 , C07C233/14 , C07C233/23 , C07C233/52 , C07C233/65 , C07C233/74 , C07C235/54 , C07C237/22 , C07C237/48 , C07C255/24 , C07C255/58 , C07C271/22 , C07C2102/08 , C07C2102/10
摘要: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, convulsions, or seizures are treated by administering a compound of the formula: ##STR1##
摘要翻译: 描述了1-氨基茚满及其盐的新型衍生物。 通过使所需化合物的N-苄基类似物与扁桃酸的对映异构体反应来制备光学活性的1-氨基茚满衍生物。 帕金森病,痴呆,癫痫,惊厥或癫痫发作通过施用下式化合物治疗:
-
公开(公告)号:US07598420B1
公开(公告)日:2009-10-06
申请号:US12283105
申请日:2008-09-08
申请人: Jeffrey Sterling , David Lerner , Harel Rosen , Leonid Bronov , Dalia Medini-Green , Berta Iosefzon , Tirtsah Berger-Peskin , Ramy Lidor-Hadas , Eliezer Bahar
发明人: Jeffrey Sterling , David Lerner , Harel Rosen , Leonid Bronov , Dalia Medini-Green , Berta Iosefzon , Tirtsah Berger-Peskin , Ramy Lidor-Hadas , Eliezer Bahar
IPC分类号: C07C211/42 , C07C209/84
CPC分类号: A61K31/135 , A61K9/2018 , A61K9/2059 , C07C211/42
摘要: The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.
摘要翻译: 本发明提供包含N-炔丙基-1(R) - 氨基茚满甲磺酸酯的药物组合物; 药学上可接受的载体; 和具有以下结构的化合物的总和大于0.7ppm但小于30ppm:和化合物的任何盐。
-
公开(公告)号:US07572834B1
公开(公告)日:2009-08-11
申请号:US11634916
申请日:2006-12-05
申请人: Jeffrey Sterling , David Lerner , Harel Rosen , Leonid Bronov , Dalia Medini-Green , Berta Iosefzon , Tirtsah Berger-Peskin , Ramy Lidor-Hadas , Eliezer Bahar
发明人: Jeffrey Sterling , David Lerner , Harel Rosen , Leonid Bronov , Dalia Medini-Green , Berta Iosefzon , Tirtsah Berger-Peskin , Ramy Lidor-Hadas , Eliezer Bahar
IPC分类号: A61K31/135 , C07C211/42
CPC分类号: A61K31/135 , A61K9/2018 , A61K9/2059 , C07C211/42
摘要: The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.
-
8.
公开(公告)号:US20070093549A1
公开(公告)日:2007-04-26
申请号:US11541150
申请日:2006-09-28
IPC分类号: A61K31/325 , C07C261/02
CPC分类号: C07C269/08 , C07C271/44 , C07C271/52
摘要: Provided are processes for preparing crystalline ladostigil tartrate form A1.
摘要翻译: 提供制备A1型晶体酒石酸钠的方法。
-
公开(公告)号:US20060199974A1
公开(公告)日:2006-09-07
申请号:US11358995
申请日:2006-02-21
申请人: Lee Boulton , Ian Lennon , Eliezer Bahar
发明人: Lee Boulton , Ian Lennon , Eliezer Bahar
IPC分类号: C07C271/40
CPC分类号: C07C269/06 , C07B2200/07 , C07C29/143 , C07C209/16 , C07C2602/08 , C07C211/42 , C07C271/44 , C07C35/32
摘要: A process for manufacturing (R)-propynylaminoindans, and alternatively, a process for manufacturing (S)-propynylaminoindans. The chiral propynylaminoindans include alkoxy or alkylcarbamates derivatives. The process comprises transfer or pressure hydrogenation in the presence of an optically active catalyst to reduce 1-indanones. The chiral product, either (S)- or (R)-indanols undergo nucleophilic substitution to produce the named product. In an additional aspect, the invention relates to novel intermediates and compounds, namely, substituted indanones, substituted (S)-indanols and substituted (R)-indanols.
摘要翻译: 制备(R) - 丙炔基氨基茚满的方法,或者,制备(S) - 丙炔基氨基茚满的方法。 手性丙炔基氨基茚满包括烷氧基或烷基氨基甲酸酯衍生物。 该方法包括在光学活性催化剂存在下转移或加压氢化以还原1-茚满酮。 (S) - 或(R) - 茚满醇的手性产物经历亲核取代以产生命名的产物。 在另一方面,本发明涉及新的中间体和化合物,即取代的茚满酮,取代的(S) - 茚满醇和取代的(R) - 茚满醇。
-
公开(公告)号:US5877218A
公开(公告)日:1999-03-02
申请号:US478204
申请日:1995-06-07
申请人: Yaacov Herzig , Jeff Sterling , Alex Veinberg , Benjamin Sklarz , Ramy Lidor , Eliezer Bahar
发明人: Yaacov Herzig , Jeff Sterling , Alex Veinberg , Benjamin Sklarz , Ramy Lidor , Eliezer Bahar
IPC分类号: A01N37/18 , A01N37/34 , A61K31/135 , A61K31/137 , A61K31/16 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/195 , A61K31/196 , A61K31/215 , A61K31/216 , A61K31/24 , A61K31/27 , A61K31/275 , A61K31/277 , C07C209/04 , C07C209/88 , C07C211/00 , C07C211/38 , C07C211/42 , C07C213/10 , C07C215/44 , C07C217/74 , C07C231/20 , C07C233/05 , C07C233/06 , C07C233/23 , C07C233/74 , C07C237/04 , A61K31/13 , C07C215/00 , C07C235/00
CPC分类号: C07C237/04 , A61K31/135 , A61K31/136 , A61K31/137 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/195 , A61K31/196 , A61K31/215 , A61K31/216 , A61K31/24 , A61K31/27 , A61K31/275 , A61K31/277 , C07C209/04 , C07C209/88 , C07C211/38 , C07C211/42 , C07C213/10 , C07C215/44 , C07C217/52 , C07C217/74 , C07C231/20 , C07C233/03 , C07C233/06 , C07C233/11 , C07C233/14 , C07C233/23 , C07C233/52 , C07C233/65 , C07C233/74 , C07C235/54 , C07C237/22 , C07C237/48 , C07C255/24 , C07C255/58 , C07C271/22 , C07C2102/08 , C07C2102/10
摘要: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, convulsions, or seizures are treated by administering a compound of the formula: ##STR1##
-
-
-
-
-
-
-
-
-